It has been two years since the launch of Antican^® drug in Taiwan, the market response shows that Antican^® begins to emerge as viable alternative to surgery when treating canine perianal gland tumors with its product features. Vetco had a chance to share some views with Animal Pharm, the global leading publication in animal health industry.

For more information about the published interview, please refer to the following URL: https://animalpharm.agribusinessintelligence.informa.com/AP016423/Vetco-canine-cancer-drug-begins-to-emerge-as-viable-competitor-with-surgery.